Experimental drug fails to show slowing of dementia in blow to Alzheimer's research
![The headquarters of pharmaceutical company Roche in Switzerland.](https://cdn.mos.cms.futurecdn.net/jQMHhXQ3ob8r5fGKXUxm2k-415-80.jpg)
An Alzheimer's drug developed by Swiss company Roche could not be proven in clinical trials to slow the progression of dementia, the pharmaceutical giant said Monday.
In a statement, Roche said the drug, gantenerumab, "did not meet their primary endpoint of slowing clinical decline" in a pair of studies conducted by the company. The identical studies, which were conducted with patients over the course of two years, were held in an effort to prove that gantenerumab could preserve certain functions in early Alzheimer's patients, including problem-solving skills, memory, and judgment.
While the trials were successful in showing a slight rate of decline, neither of them were described by Roche as being "statistically significant."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"So many of our families have been directly affected by Alzheimer's, so this news is very disappointing to deliver," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and head of global product development. "We are profoundly grateful to the study participants, their care partners, and study sites for their contributions to this research."
The faults of the studies now leave a trio of Roche's competitors, Biogen, Eisai, and Eli Lilly as the leaders in the medical community's effort to get an Alzheimer's treatment on the market.
The results saw economic ramifications as well, and Reuters reported that financial services firm Credit Suisse called the studies an "unequivocal" failure. Shares of Roche fell to their lowest in seven weeks, Reuters noted, with shares of Biogen and Eli Lilly rising 3.8 percent and 2.3 percent, respectively.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Justin Klawans has worked as a staff writer at The Week since 2022. He began his career covering local news before joining Newsweek as a breaking news reporter, where he wrote about politics, national and global affairs, business, crime, sports, film, television and other Hollywood news. Justin has also freelanced for outlets including Collider and United Press International.
-
Big Tech's answer for AI-driven job loss: universal basic income
In The Spotlight A new study reveals the strengths and limitations
By Joel Mathis, The Week US Published
-
'I will not be silent' on Gaza, says Kamala Harris
Speed Read In a meeting with Israeli Prime Minister Benjamin Netanyahu, Harris supported Israel's right to defend itself while expressing a desire to end Palestinian suffering
By Arion McNicoll, The Week UK Published
-
'How long can TikTok dominate as a social network?'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Mushroom edibles are tripping up users
the explainer The psychedelics can sometimes have questionable components
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
What is sickle cell anaemia?
The Explainer The UK has approved the use of a new drug to treat a disease that predominantly affects people of colour
By Keumars Afifi-Sabet, The Week UK Published
-
Rapamycin: the popular drug for longevity among biohackers
Under the Radar Living longer may be getting easier
By Devika Rao, The Week US Published
-
The US is at risk for dengue fever
The explainer The buzz surrounding the mosquito-borne illness
By Devika Rao, The Week US Published
-
Pharmaceutical companies are warning of a rise in knockoff drugs
Under the Radar The World Health Organization is also urging consumers to be cautious
By Justin Klawans, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
FDA panel rejects ecstasy to treat PTSD
Speed Read It cited flawed study data and the potential for abuse
By Peter Weber, The Week US Published